간암병기별 치료정보 및 건강상태

• 영문명: Treatment patterns and Survival rates for Hepatocellular Carcinoma by Stage in South Korea
• 발행기관: 한국보건의료연구원
• 저자명: 양장미(Jangmi Yang) 신상진(Sangjin Shin) 최인순(In Sun Choi)
• 간행물 정보: 『근거와 가치』제4권 제1호, 28~37쪽, 전체 10쪽
• 주제분류: 의약학 > 의학일반
• 파일형태: PDF
• 발행일자: 2018.06.30

영문 초록

Objectives: Given the high incidence and mortality rate of hepatocellular carcinoma (HCC) in South Korea, this study aimed to investigate the difference of treatment patterns and survival rates by stage at diagnosis. Methods: The Korean Liver Cancer Study Group (KLCSG) and the Korean Central Cancer Registry (KCCR) jointly built a nation wide cohort of patients who were diagnosed with HCC between 2008 and 2010. Using this cohort, a total of 4,596 HCC patients were analyzed for treatment status and health outcome by liver cancer stage. Results: Mean age at the diagnosis of HCC was 59.2±11.6 years, and males comprised 77.9%. Hepatitis B was the predominant etiology (63.9%), and hepatitis C comprised 12.6%. Stage at diagnosis was 13.6%, 37.6%, 25.8%, 12.6% and 10.0% for TNM stages I, II, III, IV-A and IV-B, respectively. Initial treatment modalities were transarterial therapy in 46.3% and surgical resection in 15.8%. The 5 year survival rate by stage (I, II, III, and IV) at diagnosis were 64.5%, 54.8%, 23.5% and 4.7%, respectively. Tumor stage at diagnosis, ECOG, Child-Pugh class, age, and sex were factors independently related to survival. Conclusion: This study confirmed that transarterial therapy is the main treatment for hepatocellular patients regardless of their tumor stage and there is a significant difference in survival outcomes according to the stage of HCC at diagnosis.

목차

I. 서 론

II. 방 법

III. 결 과

III. 고찰 및 결론

키워드

Hepatocellular carcinoma Korea Survival Stage Treatment